Last reviewed · How we verify
TAS-118 plus Oxaliplatin
TAS-118 is a thymidylate synthase inhibitor, and when combined with oxaliplatin, it targets rapidly dividing cancer cells.
TAS-118 is a thymidylate synthase inhibitor, and when combined with oxaliplatin, it targets rapidly dividing cancer cells. Used for Metastatic colorectal cancer.
At a glance
| Generic name | TAS-118 plus Oxaliplatin |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Drug class | Thymidylate synthase inhibitor |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TAS-118 works by inhibiting thymidylate synthase, an enzyme involved in DNA synthesis. This leads to the inhibition of cancer cell growth and proliferation. When combined with oxaliplatin, a platinum-based chemotherapy drug, the combination targets rapidly dividing cancer cells, leading to cell death.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAS-118 plus Oxaliplatin CI brief — competitive landscape report
- TAS-118 plus Oxaliplatin updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI